In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $45.00. The company’s shares closed yesterday at $22.27.
According to TipRanks, Arias is an analyst with an average return of -8.3% and a 40.00% success rate. Arias covers the Healthcare sector, focusing on stocks such as Danaher, Illumina, and 10x Genomics.
Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $41.29, representing an 85.41% upside. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $40.00 price target.
See the top stocks recommended by analysts >>
Based on Guardant Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $143.03 million and a GAAP net loss of $86.1 million. In comparison, last year the company earned a revenue of $117.4 million and had a GAAP net loss of $161.99 million
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GH in relation to earlier this year. Last month, Darya Chudova, the CTO of GH bought 6,626.00 shares for a total of $58,308.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guardant Health (GH) Company Description:
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Read More on GH:
- Guardant Health Announces Board Member Samir Kaul’s Resignation
- Guardant Health price target lowered to $54 from $64 at Craig-Hallum
- Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
- Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
- Guardant Health reports preliminary Q4 revenue $153M-$154M, consensus $146.34M
